RA

Rosalind Advisors Portfolio holdings

AUM $244M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+80.12%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$244M
AUM Growth
-$30.4M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
48
New
Increased
Reduced
Closed

Top Buys

1
+$15.7M
2
+$9.87M
3
+$9M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$7.43M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.17M

Top Sells

1
+$13.6M
2
+$12.4M
3
+$11.3M
4
REPL icon
Replimune Group
REPL
+$10.8M
5
DFTX
Definium Therapeutics
DFTX
+$10.6M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRXS icon
26
Neuraxis
NRXS
$91.8M
$1.69M 0.69%
286,138
AVTX icon
27
Avalo Therapeutics
AVTX
$838M
$1.12M 0.46%
+75,000
ANNX icon
28
Annexon
ANNX
$888M
$1.11M 0.45%
+200,000
AQST icon
29
Aquestive Therapeutics
AQST
$504M
$1.04M 0.43%
+250,000
BFRI icon
30
Biofrontera
BFRI
$11.3M
$942K 0.39%
1,163,962
+23,198
KURA icon
31
Kura Oncology
KURA
$905M
$813K 0.33%
100,000
RGNT
32
Regentis Biomaterials
RGNT
$9.58M
$768K 0.31%
251,510
ATYR
33
aTyr Pharma
ATYR
$53.2M
– –
-1,039,080
GUTS icon
34
Fractyl Health
GUTS
$128M
– –
-385,731
AVBP icon
35
ArriVent BioPharma
AVBP
$1.41B
– –
-215,871
XNTK icon
36
State Street SPDR NYSE Technology ETF
XNTK
$2.2B
– –
0
VTGN icon
37
VistaGen Therapeutics
VTGN
$25M
– –
0
VKTX icon
38
Viking Therapeutics
VKTX
$3.8B
– –
0
TRVI icon
39
Trevi Therapeutics
TRVI
$2.01B
– –
-100,000
SPY icon
40
State Street SPDR S&P 500 ETF Trust
SPY
$782B
– –
0
RZLT icon
41
Rezolute
RZLT
$318M
– –
0
REPL icon
42
Replimune Group
REPL
$718M
– –
-1,410,497
QURE icon
43
uniQure
QURE
$1.8B
– –
0
QQQ icon
44
Invesco QQQ Trust
QQQ
$492B
– –
0
OEF icon
45
iShares S&P 100 ETF
OEF
$20.7B
– –
0
OCUL icon
46
Ocular Therapeutix
OCUL
$1.97B
– –
-400,000
CYTK icon
47
Cytokinetics
CYTK
$10.4B
– –
-195,045
AVXL icon
48
Anavex Life Sciences
AVXL
$281M
– –
0
1
2